Oxurion to Participate in Upcoming Investor Conferences
01 Juin 2022 - 7:15PM
Leuven, BELGIUM, Boston, MA, US
– June 1, 2022 –
Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company
developing next generation standard of care ophthalmic therapies,
with clinical stage assets in vascular retinal disorders, announced
today that Michael Dillen, Chief Business Officer, will participate
in two investor conferences in June.
BIO International
2022June 13-14, 2022 | San Diego, CA
The JMP Securities Life Sciences ConferenceJune
15, 2022, 11:30 a.m. ET | New York, NYA live webcast and 90-day
archive will be available in the “Investors” section of the
Company’s website.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 479 783583michael.dillen@oxurion.com |
USConway CommunicationsBeth
Kurthbkurth@conwaycommsir.com ICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com |
- OXUR June Conferences 2022.0601
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024